While the role of PI3K inhibition has been thoroughly explored in relation to asthma and COPD, the severe hypersensitivity pneumonitis experienced by a small number of patients receiving idelalisib rings a note of caution [139]. Here, PIK3CB is linked to chronic obstructive pulmonary disease.